Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H16NO3.Na |
Molecular Weight | 317.3143 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCC(C([O-])=O)C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O
InChI
InChIKey=MEWDXXPKUBKKJO-UHFFFAOYSA-M
InChI=1S/C18H17NO3.Na/c1-2-15(18(21)22)12-7-9-14(10-8-12)19-11-13-5-3-4-6-16(13)17(19)20;/h3-10,15H,2,11H2,1H3,(H,21,22);/q;+1/p-1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1965501
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1965501
Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis. Indobufen under brand name ibustrin is used in Italy for the following conditions: cerebrovascular insufficiency, atherosclerosis of peripheral and cerebral vessels, thrombophlebitis, deep vein thrombosis, and diabetes mellitus. In addition, this drug has been investigated in the phase II clinical trial for the prevention of thromboembolic events in patients with nonrheumatic atrial fibrillation. After oral administration, it is quickly and completely absorbed.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1965501 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Preventing | Ibustrin Approved UseUnknown |
|||
Preventing | Ibustrin Approved UseUnknown |
|||
Preventing | Ibustrin Approved UseUnknown |
|||
Palliative | Ibustrin Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients (TISS Study). Ticlopidine Indobufen Stroke Study. | 1997 Jan-Feb |
|
Long term anticoagulation or antiplatelet treatment. Drug name was incorrect. | 2001 Jul 28 |
|
Thromboembolic complications after total hip replacement. | 2002 |
|
Protein binding of indobufen enantiomers: pharmacokinetics of free fraction-studies after single or multiple doses of rac-indobufen. | 2002 Oct |
|
Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]. | 2003 Aug 26 |
|
Atrial fibrillation and anticoagulation. | 2004 Oct |
|
Indobufen inhibits tissue factor in human monocytes through a thromboxane-mediated mechanism. | 2006 Jan |
|
Clinical management of adult patients with a history of nonsteroidal anti-inflammatory drug-induced urticaria/angioedema: update. | 2007 Mar 15 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00244426
indobufen capsules 100 and 200 mg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3666587
At low concentrations (10 microM), indobufen completely inhibited secondary platelet aggregation, the release reaction and TxB2 production stimulated by ADP, epinephrine and low concentrations of platelet-activating factor (PAF acether). Higher concentrations of indobufen (100 microM) completely inhibited TxB2 production, platelet aggregation and ATP release induced by arachidonic acid (1 mM) or collagen (2 micrograms/ml). The inhibitory effect was partially overcome by higher concentrations of arachidonic acid (2 mM).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Fri Dec 15 16:16:15 UTC 2023 , Edited by admin on Fri Dec 15 16:16:15 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C96751
Created by
admin on Fri Dec 15 16:16:15 UTC 2023 , Edited by admin on Fri Dec 15 16:16:15 UTC 2023
|
PRIMARY | |||
|
SUB02674MIG
Created by
admin on Fri Dec 15 16:16:15 UTC 2023 , Edited by admin on Fri Dec 15 16:16:15 UTC 2023
|
PRIMARY | |||
|
94135-04-3
Created by
admin on Fri Dec 15 16:16:15 UTC 2023 , Edited by admin on Fri Dec 15 16:16:15 UTC 2023
|
PRIMARY | |||
|
302-872-0
Created by
admin on Fri Dec 15 16:16:15 UTC 2023 , Edited by admin on Fri Dec 15 16:16:15 UTC 2023
|
PRIMARY | |||
|
91668149
Created by
admin on Fri Dec 15 16:16:15 UTC 2023 , Edited by admin on Fri Dec 15 16:16:15 UTC 2023
|
PRIMARY | |||
|
DTXSID50916344
Created by
admin on Fri Dec 15 16:16:15 UTC 2023 , Edited by admin on Fri Dec 15 16:16:15 UTC 2023
|
PRIMARY | |||
|
100000086405
Created by
admin on Fri Dec 15 16:16:15 UTC 2023 , Edited by admin on Fri Dec 15 16:16:15 UTC 2023
|
PRIMARY | |||
|
Y7A7KH8465
Created by
admin on Fri Dec 15 16:16:15 UTC 2023 , Edited by admin on Fri Dec 15 16:16:15 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD